Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Entrectinib Breakthrough Designation for NTRK+ Solid Tumors

May 17th 2017

The FDA has granted a breakthrough therapy designation to entrectinib for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or who have no acceptable standard therapies.

Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster

May 16th 2017

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.

Optimal Sequencing in EGFR-Mutant NSCLC Remains a Work in Progress

May 15th 2017

Ramaswamy Govindan, MD, discusses the rapid therapeutic changes in NSCLC and the sequencing questions physicians are currently asking.

Chemotherapy/Immunotherapy Combinations in Lung Cancer

May 12th 2017

The Changing Immunotherapy Landscape in Lung Cancer

May 12th 2017

Efficacy and Safety of Checkpoint Inhibitors in Lung Cancer

May 12th 2017

Maintenance Strategies in Lung Cancer

May 12th 2017

Lung Adenocarcinoma: The Evolving Role of Chemotherapy

May 12th 2017

Importance of Chemotherapy in Lung Cancer

May 12th 2017

Important Long-Term Considerations in Lung Cancer

May 12th 2017

Initial Treatment Approach in Lung Cancer

May 12th 2017

PD-L1 Status: What Is the Current Role?

May 12th 2017

Current and Future Biomarker Testing in Lung Cancer

May 12th 2017

Pathology and Treatment Decisions in Lung Cancer

May 12th 2017

Diagnosing Lung Adenocarcinoma: Biopsying Adequate Tissue

May 12th 2017

The Pathologic Workup of Lung Adenocarcinoma

May 12th 2017

Durvalumab Improves PFS in Phase III NSCLC Trial

May 12th 2017

Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard care with platinum-based chemotherapy and radiotherapy.

Dr. Govindan on the Future of EGFR-Mutant NSCLC

May 11th 2017

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Morgensztern on Impact of Immunotherapy on NSCLC Field

May 11th 2017

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).

Dr. Devarakonda on Biomarkers Beyond PD-L1 in NSCLC

May 11th 2017

Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).